Lek Expands Biosimilar Production

Slovenian pharmaceutical company Lek, a division of Novartis's generic arm Sandoz, has opened a new US$3.8mn biopharmaceutical production facility to produce biosimilar epoetin alfa. Sandoz markets epoetin alfa products under the trade names Binocrit and Epoetin alfa Hexal in the EU, following approval from the European Medicines Agency (EMA) in 2007, while also marketing its products elsewhere in Europe and globally. BMI believes the move should help Sandoz to meet increasing demand for biosimilar products, mainly in the EU and other markets in Emerging Europe, the main focus of Lek's current

To read the full article, please choose one of the following options: